Startup aims to develop drugs against antibiotic-resistant bacteria

04/11/2010 | American City Business Journals

Synereca Pharmaceuticals, a startup formed by the University of North Carolina at Chapel Hill, licensed rights to use a professor's research on potential treatments for antibiotic-resistant bacteria. The company plans to develop drugs that inhibit the RecA enzyme, which plays an important role in antibiotic resistance.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC